Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pluvicto
Pharma
Novartis gears up for key expansions of 3 cancer drugs
Pluvicto, Ksiqali and Scemblix have key new indications lined up for them in earlier treatment settings. But they all slightly disappointed in Q1.
Angus Liu
Apr 23, 2024 3:37pm
Novartis gears up for Pluvicto filing as survival data clear up
Apr 5, 2024 3:00am
Exelixis joins Novartis on FDA waiting list in prostate cancer
Jan 25, 2024 8:00am
Novartis' largest Pluvicto plant approved by FDA
Jan 5, 2024 11:36am
Novartis commits $85M to build radiotherapy plant in China
Dec 1, 2023 11:06am
Novartis delays Pluvicto filing as CEO spots industry conundrum
Oct 24, 2023 10:22am